About Contact Dermatitis

 

Contact dermatitis is a localized inflammatory reaction of the skin resulting from direct exposure to an external substance. It is broadly classified into two principal forms — irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD) — which, while clinically similar, differ fundamentally in their underlying mechanisms, exposure thresholds, and management implications. Less common variants include phototoxic and photoallergic contact dermatitis (in which a reaction requires both contact with a substance and ultraviolet exposure), systemic contact dermatitis (a generalized reaction following systemic exposure to an allergen previously encountered topically), and protein contact dermatitis (an immediate-type hypersensitivity reaction most often seen in food handlers).

Irritant contact dermatitis is the more common of the two principal forms, accounting for approximately 80% of cases. It arises from direct cytotoxic injury to the skin and may follow either a single, intense exposure (acute ICD) or repeated, cumulative exposure to mild irritants (chronic cumulative ICD). Allergic contact dermatitis, in contrast, is a delayed-type (type IV) hypersensitivity reaction that requires prior sensitization to a specific allergen and subsequent re-exposure to elicit the clinical reaction.

Clinically, contact dermatitis presents with erythema, edema, vesiculation, oozing, and crusting in the acute phase, progressing to scaling, lichenification, fissuring, and hyperpigmentation in chronic disease. Distribution is typically confined to the area of contact, although in allergic forms, lesions may extend beyond the immediate contact site, become widespread, or manifest in distant locations through autoeczematization (id reaction). The hands are the most commonly affected anatomical site, followed by the face, eyelids, neck, and feet.

​

Causes

 

The pathogenesis of contact dermatitis differs by subtype, with irritant and allergic forms governed by distinct mechanisms despite their overlapping clinical features:

The first is direct cytotoxic injury, the defining mechanism of irritant contact dermatitis. Exposure to chemical or physical irritants disrupts the stratum corneum, denatures keratin, damages cell membranes, and releases pro-inflammatory mediators including IL-1α, IL-6, IL-8, and TNF-α from keratinocytes. No prior sensitization is required, and reaction severity is dose-dependent, related to exposure duration, concentration, and the integrity of the underlying skin barrier. The second is delayed-type hypersensitivity, the defining mechanism of allergic contact dermatitis. Low-molecular-weight haptens penetrate the epidermis, bind to carrier proteins, and are processed by Langerhans cells and dermal dendritic cells, which migrate to regional lymph nodes and prime hapten-specific T lymphocytes. Upon subsequent exposure, these primed T cells mediate a Th1- and Th17-driven inflammatory response within 24 to 72 hours, producing the characteristic clinical reaction. The third is barrier dysfunction, a critical predisposing factor common to both subtypes, in which impaired stratum corneum integrity facilitates penetration of irritants and allergens and amplifies the inflammatory response.

The list of recognized triggers is extensive. Common irritants include water (notably in wet-work occupations), soaps, detergents, solvents, acids, alkalis, oxidizers, disinfectants, friction, and low humidity. Common allergens include nickel (the most frequent contact allergen worldwide), fragrance mixes, balsam of Peru, preservatives such as methylisothiazolinone and formaldehyde releasers, paraphenylenediamine (PPD) in hair dyes, rubber accelerators, topical antibiotics such as neomycin, topical anesthetics, plant antigens including those of the Toxicodendron genus (poison ivy, oak, sumac), and a wide range of medications, cosmetics, and personal care ingredients. Occupational exposures account for a substantial proportion of cases, with hairdressers, healthcare workers, food handlers, construction workers, cleaners, and metalworkers at particularly elevated risk.

​

Treatment

 

Effective contact dermatitis management is individualized to subtype, severity, anatomical distribution, exposure profile, and chronicity. Therapy is largely topical, with systemic and adjunctive options reserved for severe, widespread, or refractory disease, and identification and avoidance of the causative agent forming the foundation of all treatment plans.

Topical therapies form the cornerstone of treatment for mild to moderate disease. Topical corticosteroids, selected by potency to match lesion severity and anatomical site, remain the most established anti-inflammatory agents and are appropriate for both irritant and allergic forms during acute flares. Lower-potency agents are reserved for facial, intertriginous, and pediatric use, while higher-potency formulations are employed for palmoplantar and lichenified disease. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) provide a steroid-sparing option particularly suited to sensitive areas and for long-term maintenance. Newer agents including crisaborole (a PDE-4 inhibitor) and topical JAK inhibitors such as ruxolitinib offer additional non-steroidal anti-inflammatory options. Emollients applied liberally and consistently are essential across all phases of management, supporting barrier repair, reducing transepidermal water loss, and decreasing reactivity to subsequent exposures.

Systemic therapies are indicated for severe, widespread, or treatment-resistant disease. Short courses of oral corticosteroids (typically prednisone 0.5–1 mg/kg/day with tapering over 2 to 3 weeks) are commonly employed for acute, severe presentations such as widespread Toxicodendron dermatitis, though longer courses are avoided due to side-effect risk. For chronic, refractory cases, particularly chronic hand eczema with a contact component, treatment options include alitretinoin (where approved), ciclosporin, methotrexate, azathioprine, and mycophenolate mofetil. Targeted biologic and small-molecule therapies, including dupilumab and oral JAK inhibitors (upadacitinib, abrocitinib, baricitinib), have expanded the therapeutic landscape for severe, chronic disease with eczematous features.

Diagnostic and adjunctive interventions are central to long-term management. Patch testing remains the gold standard for identifying causative allergens in suspected allergic contact dermatitis and should be considered in any patient with persistent, recurrent, or unexplained eczematous disease. Phototherapy with narrowband UVB or PUVA may be useful for chronic hand and foot dermatitis. Wet-wrap therapy can provide rapid symptomatic relief in severe flares. Workplace assessment, occupational health referral, and ergonomic and behavioral modifications are essential in occupationally driven cases.

​

Solution

 

A durable solution to contact dermatitis is rarely a single intervention but rather a sustained, individualized regimen anchored in three principles: trigger identification and avoidance, inflammation control, and skin barrier support.

Trigger identification and avoidance is the cornerstone of long-term management. For irritant cases, this involves a detailed history of occupational and domestic exposures, careful review of personal care and cleaning products, and systematic reduction or elimination of cumulative low-grade insults. For allergic cases, patch testing performed by an experienced clinician is essential to identify the responsible allergen or allergens, followed by structured education on avoidance — including allergen synonyms, cross-reacting substances, and verified safe alternatives. Inflammation control involves the appropriate use of topical anti-inflammatory therapies during flares, with timely escalation to systemic or targeted agents when response is inadequate. Skin barrier support is foundational and ongoing: gentle, fragrance-free, syndet cleansing with lukewarm rather than hot water, consistent application of bland, ceramide-rich emollients, and consistent use of protective measures such as cotton-lined gloves for wet work and barrier creams in occupational settings.

Equally important are lifestyle and occupational considerations: minimizing wet-work duration, separating tasks to reduce cumulative exposure, avoiding occlusive footwear and gloves where feasible, supporting the workplace adoption of low-allergen alternatives, and addressing the psychological impact of chronic or work-disabling disease. Patients should be counseled that contact dermatitis is highly amenable to control when the causative exposure is identified and removed, that continued or covert exposure is the most common reason for treatment failure, and that adherence to a preventive routine — even during clear periods — is the strongest predictor of long-term remission.

With a structured, evidence-based approach and ongoing collaboration between patient and clinician, contact dermatitis is a highly manageable condition, and meaningful, sustained improvement in skin comfort, function, and overall quality of life is an achievable outcome for the vast majority of patients.

​

Products